Incyte Corporation

INCY

Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue
+14.0%
EPS
−277.9%
Free cash flow
−233.0%
Total debt
−10.5%

Quarter to September 2026, against a year earlier

121.89 0.38 −0.31%
Market cap
$24.9B
P/E
58.1×
Fwd P/E
57.3×
Dividend yield
—
F-score
9/9
ROIC
21.6%
Net debt / EBITDA
−2.2×
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
57.82 13.94 12.89 14.97

+8 more quarters

P/S ratio
4.10 3.90 3.50 3.75
P/FCF ratio
36.28 12.02 13.20 14.50
P/Operating CF
(36.52) 44.74 50.80 35.49
P/B ratio
4.37 3.58 3.34 3.73
EV/Sales
3.47 3.13 2.76 3.06
EV/EBITDA
28.76 9.71 8.67 9.79
EV/FCF
30.67 9.64 10.41 11.84
Current Ratio
3.84 4.59 3.68 3.32
Net Debt/EBITDA
5.59 (6.22) (12.27) (9.87)
Debt/Equity
0.00 0.00 0.01 0.01
Earnings Yield
1.73% 7.17% 7.76% 6.68%
Free Cash Flow Yield
2.76% 8.32% 7.57% 6.90%
Free Cash Flow per Share
(3.40) 2.47 1.78 2.67
Book value per Share
27.76 31.66 28.21 26.47
Free Cash Flow
(690.95) 495.25 354.15 521.42
EV/EBIT
33.28 10.24 9.18 10.39
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026